Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.63 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618139 | 0.90 | CCR3 (0.59) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5771404 | 0.87 | CCR3 (0.79) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5774092 | 0.85 | CCR3 (0.57) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5619292 | 0.85 | CCR3 (0.64) | CCR3DRD4MEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL5618690 | 0.84 | CCR3 (0.66) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5774804 | 0.84 | CCR3 (0.65) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5776845 | 0.83 | CCR3 (0.74) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5618366 | 0.83 | CCR3 (0.59) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5776992 | 0.83 | CCR3 (0.59) | CCR3DRD4MEN1KMT2AKCNH2 | |
| SCHEMBL5778646 | 0.83 | CCR3 (0.83) | CCR3DRD4MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487454-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | claimed |
| WO-2003082295-A1 | MORPHOLINE DERIVATIVES SUBSTITUTED AT THE 2-POSITION BY A HETEROCYCLYLALKYLUREA GROUP FOR USE AS CCR-3 ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | CCR3 39/4885DRD4 1474/4885MEN1 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.